CFMS
Conformis, Inc. [CFMS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CFMS Stock Summary
In the News
CFMS Financial details
Company Rating
Neutral
Market Cap
17.88M
Income
-41.5M
Revenue
57.06M
Book val./share
4.38
Cash/share
3.58
Dividend
-
Dividend %
-
Employees
295
Optionable
No
Shortable
Yes
Earnings
31 Oct 2023
P/E
-0.4
Forward P/E
-
PEG
-0
P/S
0.31
P/B
0.52
P/C
0.63
P/FCF
-0.38
Quick Ratio
3.15
Current Ratio
5.07
Debt / Equity
0.83
LT Debt / Equity
0.77
-
-
EPS (TTM)
-5.71
EPS next Y
-
EPS next Q
-
EPS this Y
1841.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.61%
Revenue last 5Y
-7.12%
Revenue Q/Q
1.45%
EPS Q/Q
34.85%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.01%
Inst Trans
1%
ROA
-61%
ROE
-86%
ROC
-0.71%
Gross Margin
33%
Oper. Margin
-71%
Profit Margin
-73%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.05-7.25
52W High
-67.57%
52W Low
+127%
RSI
-
Rel Volume
0.05
Avg Volume
156.85K
Volume
7.08K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.42293
-
-
Volatility
0.01%, 0.01%
Prev Close
0.44%
Price
2.27
Change
0.44%
CFMS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 38.12 | 30.19 | 23.98 | 14.97 | 8.59 | |
| Net income per share | -18.41 | -11.1 | -8.47 | -0.36 | -6.99 | |
| Operating cash flow per share | -11.46 | -1.11 | -6.38 | -1.26 | -6.95 | |
| Free cash flow per share | -13.18 | -2.25 | -7.52 | -1.6 | -7.21 | |
| Cash per share | 10.03 | 10.29 | 10 | 15.08 | 6.74 | |
| Book value per share | 15.37 | 6.37 | 3.96 | 15.08 | 7.5 | |
| Tangible book value per share | 15.32 | 6.37 | 3.96 | 15.08 | 7.34 | |
| Share holders equity per share | 15.37 | 6.37 | 3.96 | 15.08 | 7.5 | |
| Interest debt per share | 7.7 | 11.35 | 11.58 | 4.82 | 4.09 | |
| Market cap | 21.08M | 96.18M | 47.32M | 126.97M | 23.97M | |
| Enterprise value | 19.49M | 95.95M | 49.48M | 55.07M | 2.8M | |
| P/E ratio | -0.49 | -3.38 | -1.95 | -52.62 | -0.47 | |
| Price to sales ratio | 0.23 | 1.24 | 0.69 | 1.27 | 0.39 | |
| POCF ratio | -0.78 | -33.89 | -2.58 | -15.12 | -0.48 | |
| PFCF ratio | -0.68 | -16.69 | -2.19 | -11.87 | -0.46 | |
| P/B Ratio | 0.58 | 5.88 | 4.16 | 1.26 | 0.44 | |
| PTB ratio | 0.58 | 5.88 | 4.16 | 1.26 | 0.44 | |
| EV to sales | 0.22 | 1.24 | 0.72 | 0.55 | 0.05 | |
| Enterprise value over EBITDA | -0.62 | -3.87 | -1.98 | 12.69 | -0.06 | |
| EV to operating cash flow | -0.72 | -33.81 | -2.7 | -6.56 | -0.06 | |
| EV to free cash flow | -0.63 | -16.65 | -2.29 | -5.15 | -0.05 | |
| Earnings yield | -2.06 | -0.3 | -0.51 | -0.02 | -2.11 | |
| Free cash flow yield | -1.47 | -0.06 | -0.46 | -0.08 | -2.17 | |
| Debt to equity | 0.41 | 1.6 | 2.71 | 0.28 | 0.51 | |
| Debt to assets | 0.23 | 0.36 | 0.43 | 0.2 | 0.29 | |
| Net debt to EBITDA | 0.05 | 0.01 | -0.09 | -16.56 | 0.46 | |
| Current ratio | 4.22 | 2.94 | 1.73 | 7.06 | 5.63 | |
| Interest coverage | -11.53 | -8.54 | -10.58 | 0.02 | -22.92 | |
| Income quality | 0.62 | 0.1 | 0.75 | 3.48 | 0.99 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.27 | 0.27 | 0.35 | 0.29 | 0.46 | |
| Research and developement to revenue | 0.19 | 0.16 | 0.17 | 0.15 | 0.25 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0.01 | |
| Capex to operating cash flow | 0.15 | 1.03 | 0.18 | 0.27 | 0.04 | |
| Capex to revenue | -0.05 | -0.04 | -0.05 | -0.02 | -0.03 | |
| Capex to depreciation | -0.98 | -0.69 | -0.74 | -0.54 | -0.48 | |
| Stock based compensation to revenue | 0.04 | 0.04 | 0.05 | 0.04 | 0.03 | |
| Graham number | 79.79 | 39.9 | 27.49 | 11.08 | 34.36 | |
| ROIC | -0.76 | -0.51 | -0.52 | 0 | -0.52 | |
| Return on tangible assets | -0.69 | -0.39 | -0.34 | -0.02 | -0.54 | |
| Graham Net | 4.95 | -5.92 | -6.22 | 10.56 | 3.56 | |
| Working capital | 36.58M | 34.66M | 22.43M | 108.92M | 65.2M | |
| Tangible asset value | 36.09M | 16.35M | 11.37M | 100.55M | 52.98M | |
| Net current asset value | 21.17M | -3.54M | -6.79M | 82.09M | 39.4M | |
| Invested capital | 0.41 | 1.6 | 2.71 | 0.28 | 0.51 | |
| Average receivables | 13.29M | 12.31M | 10.5M | 9.57M | 9.63M | |
| Average payables | 4.17M | 5.18M | 5.92M | 5.74M | 5.36M | |
| Average inventory | 9.36M | 10.8M | 12.33M | 13.89M | 17.06M | |
| Days sales outstanding | 54.43 | 52.94 | 51.87 | 34.21 | 58.28 | |
| Days payables outstanding | 30.44 | 62.07 | 51.22 | 70.02 | 39.12 | |
| Days of inventory on hand | 84.25 | 108.3 | 131.07 | 162.36 | 177.72 | |
| Receivables turnover | 6.71 | 6.89 | 7.04 | 10.67 | 6.26 | |
| Payables turnover | 11.99 | 5.88 | 7.13 | 5.21 | 9.33 | |
| Inventory turnover | 4.33 | 3.37 | 2.78 | 2.25 | 2.05 | |
| ROE | -1.2 | -1.74 | -2.14 | -0.02 | -0.93 | |
| Capex per share | -1.72 | -1.14 | -1.13 | -0.34 | -0.27 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.12 | 1.9 | 2.4 | 1.77 | 1.78 | |
| Net income per share | -2.15 | -2.1 | -0.51 | -1.32 | -1.78 | |
| Operating cash flow per share | -1.34 | -1.66 | -1.57 | -1.36 | -1.54 | |
| Free cash flow per share | -1.38 | -1.74 | -1.61 | -1.48 | -1.59 | |
| Cash per share | 10.07 | 8.22 | 6.71 | 5.21 | 3.58 | |
| Book value per share | 10.18 | 8.44 | 7.47 | 6.15 | 4.38 | |
| Tangible book value per share | 10.18 | 8.44 | 7.31 | 6.15 | 4.38 | |
| Share holders equity per share | 10.18 | 8.44 | 7.47 | 6.15 | 4.38 | |
| Interest debt per share | 3.96 | 3.91 | 3.87 | 3.83 | 3.72 | |
| Market cap | 63.82M | 34.65M | 24.07M | 11.68M | 16.02M | |
| Enterprise value | 19.3M | 2.9M | 2.9M | 1.02M | 16.42M | |
| P/E ratio | -1.03 | -0.57 | -1.62 | -0.31 | -0.31 | |
| Price to sales ratio | 4.17 | 2.51 | 1.38 | 0.91 | 1.23 | |
| POCF ratio | -6.61 | -2.88 | -2.12 | -1.19 | -1.42 | |
| PFCF ratio | -6.41 | -2.74 | -2.06 | -1.09 | -1.38 | |
| P/B Ratio | 0.87 | 0.57 | 0.44 | 0.26 | 0.5 | |
| PTB ratio | 0.87 | 0.57 | 0.44 | 0.26 | 0.5 | |
| EV to sales | 1.26 | 0.21 | 0.17 | 0.08 | 1.26 | |
| Enterprise value over EBITDA | -1.65 | -0.26 | -0.43 | -0.11 | -1.44 | |
| EV to operating cash flow | -2 | -0.24 | -0.26 | -0.1 | -1.45 | |
| EV to free cash flow | -1.94 | -0.23 | -0.25 | -0.09 | -1.42 | |
| Earnings yield | -0.24 | -0.44 | -0.15 | -0.82 | -0.81 | |
| Free cash flow yield | -0.16 | -0.36 | -0.49 | -0.92 | -0.72 | |
| Debt to equity | 0.38 | 0.46 | 0.51 | 0.61 | 0.83 | |
| Debt to assets | 0.24 | 0.27 | 0.29 | 0.33 | 0.39 | |
| Net debt to EBITDA | 3.8 | 2.88 | 3.12 | 1.13 | -0.04 | |
| Current ratio | 5.71 | 5.07 | 5.63 | 5.71 | 5.07 | |
| Interest coverage | -28.15 | -22.79 | -11.54 | -14.8 | -18.42 | |
| Income quality | 0.62 | 0.79 | 3.06 | 1.03 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.5 | 0.55 | 0.24 | 0.55 | 0.61 | |
| Research and developement to revenue | 0.26 | 0.27 | 0.19 | 0.19 | 0.17 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.05 | 0.03 | 0.09 | 0.03 | |
| Capex to revenue | -0.02 | -0.04 | -0.02 | -0.07 | -0.02 | |
| Capex to depreciation | -0.29 | -0.64 | -0.34 | -0.98 | -0.34 | |
| Stock based compensation to revenue | 0.06 | 0.06 | -0.01 | 0.05 | 0.03 | |
| Graham number | 22.21 | 19.95 | 9.28 | 13.51 | 13.23 | |
| ROIC | -0.12 | -0.12 | -0.08 | -0.12 | -0.19 | |
| Return on tangible assets | -0.13 | -0.15 | -0.04 | -0.12 | -0.19 | |
| Graham Net | 6.16 | 4.47 | 3.54 | 2.31 | 0.79 | |
| Working capital | 83.13M | 71.29M | 65.2M | 55.78M | 43.85M | |
| Tangible asset value | 73.43M | 61.17M | 52.98M | 44.63M | 32.03M | |
| Net current asset value | 56.91M | 45.38M | 39.4M | 30.32M | 18.86M | |
| Invested capital | 0.38 | 0.46 | 0.51 | 0.61 | 0.83 | |
| Average receivables | 10.24M | 9.65M | 9.76M | 9.29M | 8.23M | |
| Average payables | 6.17M | 6.87M | 5.36M | 4.16M | 3.87M | |
| Average inventory | 16.19M | 17.37M | 18.46M | 19.2M | 19.26M | |
| Days sales outstanding | 57.04 | 62.77 | 51.18 | 60.8 | 53.88 | |
| Days payables outstanding | 65.69 | 66.16 | 36.5 | 48.46 | 28.83 | |
| Days of inventory on hand | 153.07 | 181.64 | 165.8 | 226.8 | 153.02 | |
| Receivables turnover | 1.58 | 1.43 | 1.76 | 1.48 | 1.67 | |
| Payables turnover | 1.37 | 1.36 | 2.47 | 1.86 | 3.12 | |
| Inventory turnover | 0.59 | 0.5 | 0.54 | 0.4 | 0.59 | |
| ROE | -0.21 | -0.25 | -0.07 | -0.21 | -0.41 | |
| Capex per share | -0.04 | -0.08 | -0.04 | -0.13 | -0.04 |
CFMS Frequently Asked Questions
What is Conformis, Inc. stock symbol ?
Conformis, Inc. is a US stock , located in Billerica of Ma and trading under the symbol CFMS
What is Conformis, Inc. stock quote today ?
Conformis, Inc. stock price is $2.27 today.
Is Conformis, Inc. stock public?
Yes, Conformis, Inc. is a publicly traded company.
Company Profile
- Volume Average 156.85K
- Market Capitalization 17.88M
- Employee 295
- CEO Mr. Mark A. Augusti
- Headquarters Billerica,MA,US
- IPO Date 2015-07-01
-
Website
https://www.conformis.com 
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
